| Upcoming Events | |
|---|---|
| Details on upcoming events are not yet available. Please click here to be notified of all upcoming events. | |
| Archived Events | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jan 24, 2012 8:30 AM ET |
Johnson & Johnson Fourth Quarter and Full Year 2011 Earnings Meeting and Webcast
Speaker(s): William C. Weldon, Chairman of the Board and Chief Executive Officer; Dominic J. Caruso, Vice President, Finance and Chief Financial Officer; and Louise Mehrotra, Vice President, Investor Relations
Contact: Homepage |
||||||||||
|
Oct 18, 2011 8:30 AM ET |
Johnson & Johnson Third Quarter 2011 Earnings Conference Call
|
||||||||||
|
May 26, 2011 9:00 AM ET |
Johnson & Johnson Pharmaceuticals Business Review
|
||||||||||
|
Apr 27, 2011 8:30 AM ET |
Johnson & Johnson and Synthes Announce Definitive Merger Agreement Conference Call
Speaker(s): Louise Mehrotra, Vice President, Investor Relations, Johnson & Johnson William C. Weldon, Chairman, Board of Directors and Chief Executive Officer, Johnson & Johnson Hansjoerg Wyss, Founder and Chairman of the Board, Synthes Alex Gorsky, Vice Chairman, Executive Committee, Office of the Chairman, Johnson & Johnson Michel Orsinger, President and Chief Executive Officer, Synthes Dominic Caruso, Vice President Finance and Chief Financial Officer, Johnson & Johnson Mike Mahoney, Worldwide Chairman, Medical Devices & Diagnostics; Johnson & Johnson
This communication shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of such securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to appropriate registration or qualification under the securities laws of such jurisdiction. (This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson and Synthes, Inc. Risks and uncertainties include, but are not limited to, the satisfaction of closing conditions for the acquisition, including receipt of regulatory approvals for the transaction, receipt of approval by the shareholders of Synthes for the transaction, and the possibility that the transaction will not be completed, or if completed, will not be completed on a timely basis; general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; trends toward health care cost containment; and increased scrutiny of the healthcare industry by government agencies. In addition, if and when the transaction is consummated, there will be risks and uncertainties related to Johnson & Johnson's ability to successfully integrate the products and employees of Johnson & Johnson and Synthes, as well as the ability to ensure continued performance or market growth of Synthes' products. A further list and description of these risks, uncertainties and other factors and the general risks associated with the respective businesses of Johnson & Johnson and Synthes can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 2, 2011, and Synthes' Annual Report 2010. Copies of these filings, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com, www.synthes.com or on request from Johnson & Johnson or Synthes. Neither Johnson & Johnson nor Synthes undertakes to update any forward-looking statements as a result of new information or future events or developments.) |
||||||||||
= add file to Briefcase
Click on the link below to learn more about Johnson & Johnson Podcasts
http://www.investor.jnj.com/medialist_podcast.cfm
